Drug Or Compound Screening Involving Gene Expression Patents (Class 435/6.13)
  • Patent number: 11366133
    Abstract: The sample plate has a principal plane in which a plurality of wells is arranged. The sample plate has a plurality of through-holes each allowing a sampling needle to pass through in a region of the principal plane where the wells are not provided, and positions of the wells and positions of the through-holes are designed such that when two pieces of the sample plates are arranged up and down with a predetermined positional relationship in a state in which respective principal planes are arranged in parallel each other, the through-holes of the sample plate arranged on an upper side is arranged at positions directly above respective wells of the sample plate arranged on a lower side.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: June 21, 2022
    Assignee: Shimadzu Corporation
    Inventors: Hiroyuki Minato, Takashi Inoue
  • Patent number: 11361433
    Abstract: An image display control system includes a hardware processor that acquires data of a static image of a subject, and data of a dynamic image of the subject including a plurality of frame images, analyzes the dynamic image that is acquired, and creates analysis result data based on an analysis result, and selects, on a basis of a purpose of checking of data, at least one of the data among the data of the static image that is acquired, a part of the data of the dynamic image that is acquired, and the analysis result data that is created.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: June 14, 2022
    Assignee: KONICA MINOLTA, INC.
    Inventors: Takanori Ando, Kenichi Yanagisawa, Ichirou Hamamoto, Naoki Hayashi
  • Patent number: 11352662
    Abstract: Technology provided herein relates in part to methods, processes, machines and apparatuses for determining sequences of nucleotides for nucleic acid templates in a nucleic acid sample. The technology provide herein also relates in part to methods, processes, machines and apparatuses for counting nucleic acid templates. Nucleic acid templates of a sample are tagged with nonrandom oligonucleotide adapters that include predetermined non-randomly generated sequences. The use of these nonrandom oligonucleotide adapters provides an efficient method to reduce sequencing errors, and increase the sensitivity of detection of low-frequency single nucleotide alterations.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 7, 2022
    Inventors: Taylor Jensen, Christopher Ellison
  • Patent number: 11327003
    Abstract: Non-parametric transforms such as t-distributed stochastic neighbor embedding (tSNE) are used to analyze multi-parametric data such as data derived from flow cytometry or other particle analysis systems and methods. These transforms may be included for dimensionality reduction and identification of subpopulations (e.g., gating). By nature, non-parametric transforms cannot transform new observations without training a new transformation based on the entire dataset including the new observations. The features described parameterize non-parametric transforms using a neural network thereby allowing a small training dataset to be transformed using non-parametric techniques. The training dataset may then be used to generate an accurate parametric model for assessing additional events in a manner consistent with the initial events.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: May 10, 2022
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: Jonathan Lin, Joseph Trotter, Keegan Owsley
  • Patent number: 11319540
    Abstract: Provided are peptide nucleic acid derivatives targeting a part of the human HIF-1? pre-mRNA. The peptide nucleic acid derivatives potently induce exon skipping to yield splice variants of HIF-1? mRNA in cells, and are useful to treat indications or conditions involving the overexpression of HIF-1?.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: May 3, 2022
    Assignee: OliPass Corporation
    Inventors: Shin Chung, Daram Jung, Bongjun Cho, Heungsik Yoon, Kangwon Jang
  • Patent number: 11312988
    Abstract: Provided are methods for determining if a cannabis sample comprises hemp or marijuana, or Cannabis sativa and/or Cannabis indica as well as primers and kits for use in the methods.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: April 26, 2022
    Assignee: ANANDIA LABORATORIES INC.
    Inventors: Jason Sawler, Sean Myles
  • Patent number: 11313850
    Abstract: A nanopore device includes an aperture and an electrode pair. A transimpedance amplifier converts a current signal IS that flows through the nanopore device into a voltage signal VS. The nanopore device measures small particles based on first data obtained by removing a DC component from the voltage signal VS and second data obtained based on the voltage signal VS from which the DC component has not been removed. Furthermore, the nanopore device is capable of monitoring the state of the nanopore device.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 26, 2022
    Assignee: ADVANTEST CORPORATION
    Inventor: Hiroshi Sato
  • Patent number: 11302422
    Abstract: Techniques to identify a mechanism of action of a compound using network dysregulation are disclosed herein. An example method can include selecting at least a first interaction involving at least a first gene, determining a first n-dimensional probability density of gene expression levels for the first gene and one or more genes in a control state, determining a second n-dimensional probability density of gene expression levels for the first gene and one or more genes following treatment using at least one compound, estimating changes between the first probability density and the second probability density, and determining whether the estimated changes are statistically significant.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: April 12, 2022
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Andrea Califano, Mukesh Bansal, Yishai Shimoni
  • Patent number: 11293032
    Abstract: Provided are isolated polynucleotides at least 80% identical to SEQ ID NOs: 1-479, 813-5173, 8511, 8513, 8515, 8517, 8519, 8521, 8523, 9096-9141 and 9142; and isolated polypeptides at least 80% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 624, 480-623, 625-812, 5174-7015, 7017-7021, 7024, 7026-8510, 8512, 8514, 8516, 8518, 8520, 8522, 8524, 9143-9177, such as the polypeptides set forth in SEQ ID NO:480-812, 5174-8510, 8512, 8514, 8516, 8518, 8520, 8522, 8524, and 9143-9177, nucleic acid constructs comprising same, transgenic cells and plants expressing same and methods of using same for increasing yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, nitrogen use efficiency, and/or abiotic stress tolerance of a plant.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: April 5, 2022
    Assignee: Evogene Ltd.
    Inventors: Limor Poraty-Gavra, Eyal Emmanuel, Hagai Karchi
  • Patent number: 11268948
    Abstract: A nanopore device includes an aperture and an electrode pair. A transimpedance amplifier converts a current signal IS that flows through the nanopore device into a voltage signal VS. The nanopore device measures small particles based on first data obtained by removing a DC component from the voltage signal VS and second data obtained based on the voltage signal VS from which the DC component has not been removed. Furthermore, the nanopore device is capable of monitoring the state of the nanopore device.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: March 8, 2022
    Assignee: ADVANTEST CORPORATION
    Inventor: Hiroshi Sato
  • Patent number: 11268087
    Abstract: Disclosed is a novel technique of directly isolating nucleic acids from a biological sample and use of the isolated nucleic acid complexes for various applications and assays such as biobanking and sequencing.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: March 8, 2022
    Assignee: SIMPLSEQ, INC.
    Inventor: Brandon Michael Young
  • Patent number: 11261452
    Abstract: The present invention relates to the culture and manipulation of microorganisms for biotech applications, and is based on the discovery and characterization of spliced leader sequences identified in transcripts from Nannochloropsis species. In particular, the invention provides nucleic acid compositions comprising a SL sequence operably linked to a protein-encoding gene. Further provided are compositions and methods for enhanced gene expression in recombinant microorganisms as well as methods for identification and/or isolation of nucleic acid molecules tagged with a spliced leader sequence.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: March 1, 2022
    Assignee: Viridos, Inc.
    Inventors: Rekha Seshadri, Ariel S. Schwartz, Leah Soriaga, Robert C. Brown
  • Patent number: 11249093
    Abstract: The present invention provides a method for the in vitro formation and/or detection of paired helical filaments (PHF) of Tau protein, comprising incubating a mixture comprising a Tau protein preparation and a polyanionic co-factor for a pre-determined period of time under conditions that promote the formation of PHFs.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: February 15, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Rosa Crespo Rodriguez, Constantin Adrian Apetri
  • Patent number: 11238955
    Abstract: A computer-implemented method includes generating, by a processor, a set of training data for each phenotype in a database including a set of subjects. The set of training data is generated by dividing genomic information of N subjects selected with or without repetition into windows, computing a distribution of genomic events in the windows for each of N subjects, and extracting, for each window, a tensor that represents the distribution of genomic events for each of N subjects. A set of test data is generated for each phenotype in the database, a distribution of genomic events in windows for each phenotype is computed, and a tensor is extracted for each window that represents a distribution of genomic events for each phenotype. The method includes classifying each phenotype of the test data with a classifier, and assigning a phenotype to a patient.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 1, 2022
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Filippo Utro, Aldo Guzman Saenz, Chaya Levovitz, Laxmi Parida
  • Patent number: 11230725
    Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding the RNA, production host cell lines comprising the RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of the RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of the RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 25, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
  • Patent number: 11213515
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 4, 2022
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Patent number: 11208448
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: December 28, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11168365
    Abstract: Disclosed herein are compositions, probes, devices, and processes useful for detecting specific reactions and binding interactions with biological molecules. In certain embodiments, methods of binding one or more biomolecules to a solid support are disclosed. Methods of generating site-specific sequences for one or more biomolecules from a solid support are also disclosed. Biological complexes generated by these methods are also disclosed.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: November 9, 2021
    Assignee: VIBRANT HOLDINGS, LLC
    Inventor: John J. Rajasekaran
  • Patent number: 11155616
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 26, 2021
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Patent number: 11149271
    Abstract: A method of treating a subject suffering from cancer includes administering an effective amount of a RNA molecule to the subject, wherein the RNA molecule is isolated or derived from a plant of the genus Taxus. A method of inhibiting growth or proliferation of cancer cells includes contacting cancer cells with the RNA molecule; and a pharmaceutical composition for treating cancer includes the RNA molecule and a pharmaceutically tolerable excipient. Also a double-stranded RNA molecule and a recombinant vector include the double-stranded RNA molecule.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: October 19, 2021
    Inventors: Zhi-Hong Jiang, Tong-Meng Yan, Kai-Yue Cao
  • Patent number: 11130991
    Abstract: Methods, compositions and kits are provided to amplify the amount of genomic methylated DNA can by subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: September 28, 2021
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Chuan He, Boxuan Simen Zhao, Pradnya Narkhede, Chang Liu, Xiaolong Cui
  • Patent number: 11130987
    Abstract: Disclosed herein are methods of detecting a target RNA, methods of diagnosing an individual with a disease or condition when a target RNA associated with the disease or condition is detected, and methods of conveying via a communication medium data from the detection of a target RNA.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 28, 2021
    Assignee: SENTILUS HOLDCO, LLC
    Inventors: Ashutosh Chilkoti, Srinath Rangarajan, Miriam Amiram, Angus Hucknall
  • Patent number: 11118170
    Abstract: An engineered payload-delivery system includes a target cell binding unit, covalently bound to a pore forming unit, and a payload portion adapted with a region capable of non-covalently binding to the pore forming unit. The pore forming unit is derived from a particular sub-serotype of Clostridium toxin, while the payload region is derived from a different sub-serotype of Clostridium toxin. The disclosed chimeric protein-based composition is capable of specifically delivering payload to neural cells.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: September 14, 2021
    Assignee: The Board of Regents of the University of Nebraska
    Inventors: Benjamin J. Pavlik, Paul Blum, Kevin Van Cott
  • Patent number: 11118216
    Abstract: Disclosed are compositions, methods and kits for determining the presence, absence, amount, copy number, or other characteristics of one or more polynucleotide sequences in two or more samples and use thereof in genotyping, evaluation of copy number variation, expression analysis, determination of splice variants and fusion genes, and other genetic analyses.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: September 14, 2021
    Assignee: AFFYMETRIX, INC.
    Inventors: Heather Koshinsky, John D. Curry, Robert O'Callahan, Adam McCoy, Daniel Fitzpatrick, Philip H. Dickinson, Anthony C. Schweitzer
  • Patent number: 11066661
    Abstract: A system for DNA gene assembly that utilizes a DNA symbol library and a DNA linker library. The symbol library has a number of DNA symbols each having a first overhanging end and a second overhanging end different than and non-complimentary to the first end, the first and second ends being the same nucleotides for each DNA symbol. The linker library has pairs of DNA linkers, a first linker of a pair having a first overhanging end and a second overhanging end and a second linker of the pair having a first overhanging end and a second overhanging end, the first end of the first linker being the same nucleotides for each first linker and the second end of the second linker being the same nucleotides for each second linker, wherein the second end of the first linker and the first end of the second linker have complementary nucleotides. The first linker joins to the first end of a DNA symbol and the second linker joins to the second end of another DNA symbol.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: July 20, 2021
    Assignee: SEAGATE TECHNOLOGY LLC
    Inventors: Tim Rausch, Walter R Eppler, Gemma Mendonsa
  • Patent number: 11062790
    Abstract: A method for designing all coverage of valid primer pairs, which satisfy various filtering constraints provided by users with respect to a given sequence database and has validated specificity to given sequences, is provided. By screening all suitable primer pairs present on a given DNA sequence database without omitting any one primer pair and also screening all primers having a coverage of 1 or more as well as primers having a coverage of 1, a user can be allowed to give rankings to the primers in order to easily select the primers having a high success rate in biological experiments from the resulting primers.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 13, 2021
    Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Min Soo Kim, Jae Hyung Koo, Hye Rin Kim, Na Na Kang, Kang Wook Chon, Seon Ho Kim
  • Patent number: 11046962
    Abstract: Cells, including stem cells, comprising an autobioluminescent phenotype, wherein the cells emit a luminescent signal in the absence of an exogenous luminescent stimulator, are provided. The luminescent signal may be constitutive, inducible, repressible, or tissue-specific. The cells express a synthetically engineered bacterial luciferase (lux) cassette, i.e., the luxCDABEfrp gene cassette. The cells may comprise luxA, luxB, luxC, luxD, luxE, and flavin reductase. The cells may each express a combined expression level of luxC, luxD, luxE, and flavin reductase that is from ten to forty times greater than a combined expression level of luxA and luxB. Further, methods of making and using the cells comprising an autobioluminescent phenotype are disclosed herein.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: June 29, 2021
    Inventors: Daniel Close, Steven Ripp, Gary Sayler, Michael Conway
  • Patent number: 11046963
    Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to methods of increasing the expression level of a protein of interest of a bacterial host cell in a production process. The invention relates particularly to improving the capacity of a bacterial host cell to express a protein of interest by expressing a phage protein during the production process which inhibits growth of the bacterial host cell. Decoupling growth of the bacterial host cell of manufacturing of the protein of interest during the production process reduces (i) the metabolic burden, (ii) oxygen demand, (iii) metabolic heat development, and (iv) avoids stress response caused by heterologous protein expression and thereby increases the capacity of a host cell to produce the protein of interest.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 29, 2021
    Assignee: enGenes Biotech GmbH
    Inventors: Juergen Mairhofer, Gerald Striedner, Reingard Grabherr, Monika Wilde
  • Patent number: 11033902
    Abstract: A microfluidic device (1) comprising, a pallet, having a first surface (4a) and second, opposite, surface (4b); the first surface (4a) having defined therein, a main channel (5), and one or more inlet subsidiary channels (6a,6b) each of which is in fluid communication with the main channel (5) at a first junction (7) which is located at one end of the main channel (5), and corresponding one or more outlet subsidiary channels (8a,8b) each of which is in fluid communication with the main channel (5) at a second junction (9) which is located an second, opposite, end of the main channel (5); wherein the depth (‘d’) of the one or more inlet subsidiary channels (6a,6b) and the depth (‘?’) of the one or more outlet subsidiary channels (8a,8b) is less than the depth (‘f) of the main channel (5) so that there is step (106a,106b, 108a, 108b) defined at the first junction (7) and at the second junction (9); the second, opposite, surface (4b) having defined therein a groove (15) which can receive a means for generating a
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: June 15, 2021
    Assignee: RQMICRO AG
    Inventors: Daniel Schaffhauser, Hans-Anton Keserue, Georgios Akepsimaidis
  • Patent number: 11022555
    Abstract: Provided are methods for multiplex polymerase chain reaction (PCR) amplification of short tandem repeat (STR) loci that can be used to rapidly generate a highly specific STR profile from target nucleic acids. The resulting STR profiles are useful for human identification purposes in law enforcement, homeland security, military, intelligence, and paternity testing applications.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 1, 2021
    Assignee: ANDE CORPORATION
    Inventors: James W. Schumm, Richard F. Selden, Eugene Tan
  • Patent number: 11001881
    Abstract: This invention provides methods and systems for measuring the concentration of multiple nucleic acid sequences in a sample. The nucleic acid sequences in the sample are simultaneously amplified, for example, using polymerase chain reaction (PCR) in the presence of an array of nucleic acid probes. The amount of amplicon corresponding to the multiple nucleic acid sequences can be measured in real-time during or after each cycle using a real-time microarray. The measured amount of amplicon produced can be used to determine the original amount of the nucleic acid sequences in the sample. Also provided herein are biosensor arrays, systems and methods for affinity based assays that are able to simultaneously obtain high quality measurements of the binding characteristics of multiple analytes, and that are able to determine the amounts of those analytes in solution. The invention also provides a fully integrated bioarray for detecting real-time characteristics of affinity based assays.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 11, 2021
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Arjang Hassibi, Babak Hassibi, Haris Vikalo
  • Patent number: 11001868
    Abstract: Methods for in vitro transcription and translation using a double-stranded concatemeric DNA in a eukaryotic cell-free expression system are provided. The method includes the steps of (a) contacting a double-stranded concatemeric DNA with a eukaryotic cell-free expression system, and (b) expressing a protein in vitro from the double-stranded concatemeric DNA in the eukaryotic cell-free expression system. The double-stranded concatemeric DNA includes a plurality of tandem repeat sequences. The plurality of tandem repeat sequences includes an expression sequence including a promoter, a cap-independent translation element (CITE), and an open reading frame. A final concentration of the double-stranded concatemeric DNA in the eukaryotic cell-free expression system is in a range from about 0.1 ng/?L to about 35 ng/?L. A RCA product DNA may be used as the double stranded concatemer DNA for the methods.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: May 11, 2021
    Assignee: Global Life Sciences Solutions Operations UK Ltd
    Inventors: Erik Leeming Kvam, John Richard Nelson, Wei Gao
  • Patent number: 10988740
    Abstract: Methods and compositions are provided for engineering microorganisms, which permit enhanced H2 production. The methods and compositions provided include novel chimeric gene constructs encoding H2-forming H2ase and maturation proteins, allowing for generation of H2 continuously in large quantities. In one illustrated embodiment, novel engineered algae are provided with increased levels of H2 production.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: April 27, 2021
    Inventor: Svetlana Oard
  • Patent number: 10982257
    Abstract: Method for studying constituents of individual molecular complexes by labelling the molecules belonging to the same complex with at least one set of molecular constructs, wherein each set member includes a Unique Identifying Sequence (UIS), which is a nucleic acid sequence unique for each set member, and at least one Common Tag Sequence (CTS), which is a nucleic acid sequence common to all set members, by: attaching the molecular construct to the complex by ligating or hybridizing the molecular construct to a nucleic acid molecule of the complex, or ligating or hybridizing the tag to a nucleic acid linked to an affinity binder that binds specifically to a constituent of the complex; labelling the molecules belonging to the same complex using the molecular construct tags as primers or templates in a nucleic acid polymerization reaction; and analyzing the composition of the complex by analyzing combinations of UISs and CTSs.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: April 20, 2021
    Assignee: VESICODE AB
    Inventor: Di Wu
  • Patent number: 10976313
    Abstract: Multiplex immunoassays utilize the differential affinities among the conjugation pairs between the capture ligands and target analytes are proposed. Window magnetic-assisted rapid aptamer selection (window-MARAS) methods for selecting aptamers with desirable affinity toward the target analytes and methods for generating reagents for multiplex immunoassays or multiplex detection in one assay by utilizing the selected aptamers as capture ligands in reagents are described and used to demonstrate the feasibility of multiplex immunoassays based on the differential affinity of conjugation pairs between the capture ligands and target analytes.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: April 13, 2021
    Inventors: Chin-Yih Hong, Herng-Er Horng
  • Patent number: 10961499
    Abstract: The present invention relates to a new method for the production of a molecule of interest by conversion of a source of carbon in a fermentative process comprising culturing a microorganism genetically modified for the production of molecule of interest, wherein said microorganism comprises functional genes coding PTS carbohydrate utilization system and wherein the expression of proteins regulated the expression of phosphoenolpyruvate synthase (PPS) is down-regulated. The present invention also relates to the genetically modified microorganism used in the method of the invention.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: March 30, 2021
    Assignee: METABOLIC EXPLORER
    Inventors: Gwénaëlle Corre, Céline Raynaud
  • Patent number: 10945427
    Abstract: The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days).
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: March 16, 2021
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Masuhiro Nishimura, Tamaki Wada, Chikage Shirakawa, Masako Doi
  • Patent number: 10881332
    Abstract: The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: January 5, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Prashant Nagesh Kumta, Madhumati Ramanathan, Mitali Shirish Patil
  • Patent number: 10858693
    Abstract: Biosensors and methods for localized surface plasmon resonance biosensing are disclosed. The biosensor can include a substrate having a substrate surface to which a plurality of localized surface plasmon resonance (LSPR) antennae are affixed. The LSPR antennae can be affixed via an affixation surface of the LSPR antenna. The LSPR antennae can have a functional surface opposite the affixation surface. Each functional surface can be functionalized by a plurality of single-stranded DNA.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 8, 2020
    Assignee: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
    Inventors: Rajesh Sardar, Murray Korc, Gayatri K. Joshi
  • Patent number: 10858629
    Abstract: Disclosed is a new process for the production of recombinant proteins, by transient transfection of suspension-grown human embryonic kidney cells (293 cell line and its genetic variants) with an expression vector, using polyethylenimine (PEI) as a transfection reagent. In a preferred embodiment, the process uses 293E cells expressing the Epstein-Barr virus (EBV) EBNA 1 protein, in combination with an oriP-based episomal expression vector having an improved cytomegalovirus expression cassette comprising the CMV5 promoter. The process combines in a single step the cell growth, transfection and protein expression, is carried out without changing the culture medium, and allows to achieve high expression levels in a short period of time. The process may be carried out in a serum-free, low-protein culture medium, is easily scalable, compatible with continuous production processes, and fully adapted to high-throughput production of milligram quantities of recombinant proteins.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: December 8, 2020
    Assignee: National Research Council of Canada
    Inventors: Yves Durocher, Amine Kamen, Sylvie Perret, Phuong Pham
  • Patent number: 10837001
    Abstract: Disclosed herein are methods of inducing and/or promoting cardiomyocyte maturation comprising: providing an immature cardiomyocyte; providing a three dimensional (3D) cardiac extracellular matrix (ECM) scaffold; and inducing and/or promoting cardiomyocyte cell maturation by seeding the immature cardiomyocyte in the 3D cardiac ECM scaffold and harvesting once the cardiomyocyte has reached maturity. Also disclosed herein are methods of treating a disease in a mammal comprising transplanting a mature cardiomyocyte into an ischemic heart, wherein the mature cardiomyocyte is generated comprising the steps of: providing an immature cardiomyocyte; providing a 3D cardiac ECM scaffold; and generating mature cardiomyocyte by seeding the immature cardiomyocyte in a 3D cardiac ECM scaffold or co-culturing the immature cardiomyocyte in the presence of endothelial cells or stromal cells; and harvesting once the cardiomyocyte has reached maturity.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 17, 2020
    Assignee: The Regents of The University of California
    Inventors: Ashley H. Fong, Christopher C. W. Hughes
  • Patent number: 10822662
    Abstract: A method for diagnosing a lymphoid proliferative disorder (such as lymphoma, T-cell lymphoma or leukemia) in a subject or determining the risk of a subject for a lymphoid proliferative disorder recurrence after transient remission, which includes high throughput T-Cell Receptor ? (TCR?) sequencing tests to identify dominant oncogenic clones in the subject suffering from the lymphoid proliferative disorder. Oligonucleotides primer compositions and kits associated with the above-described methods are also provided herein. Said subject includes living organisms, such as mammals (e.g., dogs, cats, pigs, cows, horses, goats, rabbits, humans), non-mammalian vertebrates, such as birds (e.g., chicken, ducks), fish (e.g., sharks), or frogs, and transgenic species thereof.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 3, 2020
    Assignee: Karkinos Precision Oncology LLC
    Inventor: Adam Scott Buntzman
  • Patent number: 10808080
    Abstract: A monomer is represented by Chemical Formula 1: wherein, in Chemical Formula 1, R1, R2, o, p, L1, A1, Ra, m, and n are the same as defined in the detailed description.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 20, 2020
    Assignee: SAMSUNG ELECTRONICS CO, LTD.
    Inventors: Dmitry Androsov, Changki Kim, Kalinina Fedosya, Hyunseok Choi
  • Patent number: 10774361
    Abstract: The invention relates to a method for identifying unknown microbes in a sample, wherein a mass spectrometric determination down to the taxonomic level of the genus or species is supplemented by a detailed determination of a lower taxonomic level or variety by means of infrared spectrometry, using restricted reference libraries of infrared spectra. These libraries can be genus-specific, containing only infrared spectra of microbes of one genus, or species-specific, containing only infrared spectra of microbes of one species. In so doing, a robust mass spectrometric identification of the species of unknown microbes is advantageously supplemented with a detailed analysis of the subspecies and varieties by means of infrared spectrometry, primarily in order to identify medically important varieties such as pathovars like EHEC and EPEC, and antibiotic-resistant microbes like MRSA.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 15, 2020
    Inventor: Markus Kostrzewa
  • Patent number: 10767207
    Abstract: Fungal glucoamylases from Aspergillus fumigatus—expressed in Trichoderma reesei host cells (AfGATR) are provided. Trichoderma reesei host cells express AfGATRs at higher, or at least comparable, levels to natively expressed AfGA Aspergillus fumigatus. AfGATRs, including AfGA1TR and AfGA2TR, exhibit high activity at elevated temperatures and at low pH, so AfGATRs can be used efficiently in a process of saccharification in the presence of alpha-amylase, such as Aspergillus kawachii alpha-amylase (AkAA). AfGATRs advantageously catalyze starch saccharification to an oligosaccharide composition significantly enriched in DP1 (i.e., glucose) compared to the products of saccharification catalyzed by Aspergillus niger glucoamylase (AnGA) or native AfGA expressed in Aspergillus fumigatus. AfGATRs such as AfGA1TR, AfGA2TR or a variant thereof can be used at a lower dosage than AnGA and natively expressed AfGAs to produce comparable levels of glucose.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 8, 2020
    Assignee: Danisco US INC
    Inventors: Jing Ge, Ling Hua, Sung Ho Lee, Jalsen Li, Jayarama K Shetty, Zhongmei Tang, Bo Zhang, Kun Zhong
  • Patent number: 10745693
    Abstract: Described herein is a method for identifying synthetic inducible promoters that have specified induction and/or repression for DNA binding proteins such as an allosteric transcription factor and an inducer molecule. The method includes an in vitro selection from an unselected polynucleotide library comprising a plurality of random degeneracies, and an in vivo selection to produce an induced promoter library. Produced is an induction table, which allows the selection of a promoter with specific induction and/or repression properties. Also included are biosensors containing the synthetic inducible promoters.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: August 18, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Srivatsan Raman, Aseem Zoe Ansari, Xiangyang Liu, Jose Arcadio Rodriguez-Martinez
  • Patent number: 10699800
    Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations that make use of decision analyses. The decision analyses sometimes include segmentation analyses and/or odds ratio analyses.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 30, 2020
    Assignee: Sequenom, Inc.
    Inventors: Chen Zhao, Zeljko Dzakula, Cosmin Deciu, Sung Kyun Kim, Amin R. Mazloom, Gregory Hannum, Mathias Ehrich
  • Patent number: 10697007
    Abstract: The methods described herein, referred to as PCR-Activated Sorting (PAS), allow nucleic acids contained in biological systems to be sorted based on their sequence as detected with nucleic acid amplification techniques, e.g., PCR. The nucleic acids can be free floating or contained within living or nonliving structures, including particles, viruses, and cells. The nucleic acids can include, e.g., DNA or RNA. Systems and devices for use in practicing methods of the invention are also provided.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 30, 2020
    Assignee: The Regents of the University of California
    Inventors: Adam R. Abate, Dennis Jay Eastburn, Adam R. Sciambi, Shaun Lim
  • Patent number: 10688221
    Abstract: This invention relates to methods for decellularising human liver tissue to produce human hepatic extracellular matrix (ECM) scaffolds, for example for use in therapy or disease modelling. The methods involve mechanically damaging cells in the tissue, for example by freeze thaw, and then subjecting the liver tissue to multiple cycles of osmotic stress, detergent treatment and protease and/or DNAase treatment to produce a decellularised human ECM scaffold.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: June 23, 2020
    Assignee: UCL BUSINESS PLC
    Inventors: Giuseppe Mazza, Massimo Malago, Paolo de Coppi, Massimo Pinzani
  • Patent number: 10676742
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek